Results 41 to 50 of about 19,218 (261)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib

American Journal of Ophthalmology Case Reports, 2020
Purpose: To report a case of a locally advanced periocular basal cell carcinoma treated with neoadjuvant Vismodegib therapy prior to surgery. Observations: A 63-year-old female presented to the oculoplastics clinic with biopsy-proven basal cell carcinoma
Maxwell G. Su, Luke B. Potts, Jonathan H. Tsai   +2 more
doaj   +1 more source

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Drugs in Context, 2022
Sonidegib is a Hedgehog signalling pathway inhibitor approved for use in patients with advanced basal cell carcinoma (BCC) not eligible for surgery or radiotherapy.
Susana Puig, Carlos Serra-Guillén, Gemma Pérez-Pastor, Álvaro Martínez-Domenech, Ricardo Fernández-de-Misa Cabrera   +4 more
doaj   +1 more source

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)

Skin Health and Disease, 2023
Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic condition characterized by the early development of numerous cutaneous basal cell carcinomas (BCCs).
Federico Venturi, Luciana Trane, Flavia Silvestri, Biancamaria Zuccaro, Elisabetta Magnaterra, Vincenzo De Giorgi   +5 more
doaj   +1 more source

Levels of circulating soluble receptor activator of NF-κB and interleukins-1 predicting outcome of locally advanced basal cell carcinoma. [PDF]

Int J Immunopathol Pharmacol, 2016
Lin Q, Li Y, Zhang D, Jin H.
europepmc   +2 more sources

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma [PDF]

Clinical Cancer Research, 2017
Abstract On July 24, 2015, the FDA approved sonidegib (ODOMZO; Novartis) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy. The approval was based on data from one randomized, double-blind, noncomparative trial of two doses of sonidegib administered to 230 ...
Denise, Casey, Suzanne, Demko, Stacy, Shord, Hong, Zhao, Huanyu, Chen, Kun, He, Alexander, Putman, Whitney, Helms, Patricia, Keegan, Richard, Pazdur   +9 more
openaire   +2 more sources

Anal and rectal locally advanced basal cell carcinoma treated with sonidegib

Dermatologic Therapy, 2021
N ...
Conforti, Claudio, Toffoli, Ludovica, Degrassi, Ferruccio, di Meo, Nicola, Zalaudek, Iris   +4 more
openaire   +3 more sources

Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma

, 2021
Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell ...
Scarfi F., Trane L., Silvestri F., De Giorgi V., Venturi F., Zuccaro B., Savarese I.   +6 more
core   +1 more source

Health insurance coverage, history of psychiatric disorders/dementia, and BCC treatment history in patients with locally advanced basal cell carcinoma in Cohort 1.

, 2022
Abbreviations: BCC, basal cell carcinoma; laBCC, locally advanced basal cell carcinoma. aSpecific diagnoses occurring in 2 or more patients are reported.
Simon Yoo (11949194), Aleksandar Sekulic (3192720), Laura Chu (1891477), Edward McKenna (4030052), Yong Mun (9200749), Julie Guillen (11949200), Ragini Kudchadkar (11949197), Gary Rogers (505210), Keith Dawson (11949209), Scott Guenthner (11949203), Mario Lacouture (11949212), Anne Lynn S. Chang (3339900), Bernard Raskin (11949206)   +12 more
core   +1 more source

Prostatic basal cell carcinoma treated by chemoradiation with weekly cisplatine: case report and literature review

African Journal of Urology, 2021
Background Basal cell carcinoma of the prostate is a relatively rare entity. Their evolution is characterized by the frequency of local and/or distant relapses. Due to their rarity, the treatment is not consensual in the literature. We report here a case
S. Ridai, C. Moustakbal, A. Lachgar, H. Jouhadi, A. Benider, M. Regragui, F. Marnissi   +6 more
doaj   +1 more source

Vismodegib for Locally Advanced Basal Cell Carcinoma in a Heart Transplant Patient [PDF]

JAMA Dermatology, 2015
Immunosuppressed patients with solid organ transplants have an increased risk for nonmelanoma skin cancer. Vismodegib has been reported to be effective for select locally advanced or metastatic basal cell carcinomas. However, there is no data documenting the use and safety of vismodegib in immunosuppressed organ transplant patients.We describe a 78 ...
Carrie Ann, Cusack, Rohit, Nijhawan, Brett, Miller, Mira, Henien, Gregory, Malat, Alden, Doyle, Mark, Abdelmalek   +6 more
openaire   +2 more sources